Study summary
Bimekizumab cut abscesses and nodules by half in about half of people
48%reached at least a 50% response at 16 weeks
What was tested
Bimekizumab, an antibody blocking IL-17A and IL-17F, against placebo for moderate to severe hidradenitis suppurativa, in two phase 3 trials.
What they found
- In BE HEARD I, 48% on bimekizumab every 2 weeks reached at least a 50% improvement at week 16, more than with placebo.
- Responses held or improved through 48 weeks.
- Serious side effects occurred in 5% to 8%.
What it means
Now an approved option alongside adalimumab and secukinumab.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.